SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kolb, H. J. Articles by Wilmanns, W. Search for Related Content PubMed PubMed Citation Articles by Kolb, H. J. Articles by Wilmanns, W. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients HJ Kolb, J Mittermuller, C Clemm, E Holler, G Ledderose, G Brehm, M Heim and W Wilmanns Medizinische Klinik III, Klinikum Grosshadern, Universtat Munchen, Germany. Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat. All had complete hematologic and cytogenetic remission, which persisted 32 to 91 weeks after treatment. In two patients graft-versus-host disease developed and was treated by immunosuppression. These results are an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras. Volume 76, Issue 12, pp. 2462-2465, 12/15/1990 Copyright © 1990 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. J. Wu and J. Ritz Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation Clin. Cancer Res., July 15, 2009; 15(14): 4515 - 4517. [Abstract] [Full Text] [PDF] Y. Kamiryo, M. Eto, H. Yamada, T. Yajima, M. Harano, A. Takeuchi, K. Tatsugami, M. Hamaguchi, S. Naito, and Y. Yoshikai Donor CD4 T Cells Are Critical in Allogeneic Stem Cell Transplantation against Murine Solid Tumor Cancer Res., June 15, 2009; 69(12): 5151 - 5158. [Abstract] [Full Text] [PDF] V. Nardi, O. Naveiras, M. Azam, and G. Q. Daley ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines Blood, April 16, 2009; 113(16): 3813 - 3820. [Abstract] [Full Text] [PDF] M. Haniffa, F. Ginhoux, X.-N. Wang, V. Bigley, M. Abel, I. Dimmick, S. Bullock, M. Grisotto, T. Booth, P. Taub, et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation J. Exp. Med., February 16, 2009; 206(2): 371 - 385. [Abstract] [Full Text] [PDF] L. T. van der Veken, M. Coccoris, E. Swart, J. H. F. Falkenburg, T. N. Schumacher, and M. H. M. Heemskerk {alpha}{beta} T Cell Receptor Transfer to {gamma}{delta} T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo J. Immunol., January 1, 2009; 182(1): 164 - 170. [Abstract] [Full Text] [PDF] A. Mackensen Adoptive Transfer of Tumor Antigen-specific CD8+ T-cells to Patients with Melanoma: Strategies to Improve Therapeutic Efficacy ASCO Educational Book, January 1, 2009; 2009(1): 521 - 524. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] M. Griffioen, H.M. E. van Egmond, H. Barnby-Porritt, M. A.W.G. van der Hoorn, R. S. Hagedoorn, M. G.D. Kester, N. Schwabe, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application Haematologica, October 1, 2008; 93(10): 1535 - 1543. [Abstract] [Full Text] [PDF] I. F. Khouri, P. McLaughlin, R. M. Saliba, C. Hosing, M. Korbling, M. S. Lee, L. J. Medeiros, L. Fayad, F. Samaniego, A. Alousi, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Blood, June 15, 2008; 111(12): 5530 - 5536. [Abstract] [Full Text] [PDF] M. Eto, Y. Kamiryo, A. Takeuchi, M. Harano, K. Tatsugami, M. Harada, K. Kiyoshima, M. Hamaguchi, T. Teshima, M. Tsuneyoshi, et al. Posttransplant Administration of Cyclophosphamide and Donor Lymphocyte Infusion Induces Potent Antitumor Immunity to Solid Tumor Clin. Cancer Res., May 1, 2008; 14(9): 2833 - 2840. [Abstract] [Full Text] [PDF] M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity PNAS, March 11, 2008; 105(10): 3837 - 3842. [Abstract] [Full Text] [PDF] R. Conrad, M. Remberger, K. Cederlund, O. Ringden, and L. Barkholt A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors Haematologica, February 1, 2008; 93(2): 265 - 272. [Abstract] [Full Text] [PDF] A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., January 20, 2008; 26(3): 455 - 462. [Abstract] [Full Text] [PDF] D.-P. Chen, C.-P. Tseng, S.-H. Tsai, T.-L. Wu, P.-Y. Chang, and C.-F. Sun Systematic Analysis of Stutters to Enhance the Accuracy of Chimerism Testing Ann. Clin. Lab. Sci., January 1, 2008; 38(3): 264 - 272. [Abstract] [Full Text] [PDF] S. Mackinnon Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337. [Abstract] [Full Text] [PDF] Y. Yoshida, T. Hirano, G. Son, Y. Iimuro, T. Imado, T. Iwasaki, and J. Fujimoto Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1114 - G1123. [Abstract] [Full Text] [PDF] C. Schmid, M. Labopin, A. Nagler, M. Bornhauser, J. Finke, A. Fassas, L. Volin, G. Gurman, J. Maertens, P. Bordigoni, et al. Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party J. Clin. Oncol., November 1, 2007; 25(31): 4938 - 4945. [Abstract] [Full Text] [PDF] F. Scheich, J. Duyster, C. Peschel, and H. Bernhard The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens Blood, October 1, 2007; 110(7): 2556 - 2560. [Abstract] [Full Text] [PDF] J. S. Miller, D. J. Weisdorf, L. J. Burns, A. Slungaard, J. E. Wagner, M. R. Verneris, S. Cooley, R. Wangen, S. K. Fautsch, R. Nicklow, et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone Blood, October 1, 2007; 110(7): 2761 - 2763. [Abstract] [Full Text] [PDF] F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al. Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation Blood, June 1, 2007; 109(11): 4698 - 4707. [Abstract] [Full Text] [PDF] N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse Blood, May 15, 2007; 109(10): 4564 - 4574. [Abstract] [Full Text] [PDF] P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo J. Immunol., February 15, 2007; 178(4): 2028 - 2037. [Abstract] [Full Text] [PDF] M. Eto, M. Harano, K. Tatsugami, M. Harada, Y. Kamiryo, K. Kiyoshima, M. Hamaguchi, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease Clin. Cancer Res., February 1, 2007; 13(3): 1029 - 1035. [Abstract] [Full Text] [PDF] J. H. Antin Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2 Hematology, January 1, 2007; 2007(1): 47 - 54. [Abstract] [Full Text] [PDF] J. C. Yang and R. Childs Immunotherapy for Renal Cell Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5576 - 5583. [Abstract] [Full Text] [PDF] A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma J. Clin. Oncol., November 1, 2006; 24(31): 5060 - 5069. [Abstract] [Full Text] [PDF] J. Aschan Allogeneic haematopoietic stem cell transplantation: current status and future outlook Br. Med. Bull., October 5, 2006; (2006) ldl005v2. [Abstract] [Full Text] [PDF] D. L. Porter RIC for MDS: the glass is half full Blood, August 1, 2006; 108(3): 780 - 781. [Full Text] [PDF] E. H. Slager, M. W. Honders, E. D. van der Meijden, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, M. G. D. Kester, I. Jedema, W. A. E. Marijt, M. R. Schaafsma, R. Willemze, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Blood, June 15, 2006; 107(12): 4954 - 4960. [Abstract] [Full Text] [PDF] M. J. Mauro and R. T. Maziarz Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used? Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416. [Abstract] [Full Text] [PDF] J. F. Apperley Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation Hematology, January 1, 2006; 2006(1): 226 - 232. [Abstract] [Full Text] [PDF] F. M. Kloosterboer, S. A. P. van Luxemburg-Heijs, R. A. van Soest, H. M. E. van Egmond, R. Willemze, and J. H. F. Falkenburg Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia Blood, December 1, 2005; 106(12): 3955 - 3957. [Abstract] [Full Text] [PDF] M. Harano, M. Eto, T. Iwai, K. Tatsugami, K. Kiyoshima, Y. Kamiryo, M. Tsuneyoshi, Y. Yoshikai, and S. Naito Renal Cancer Treatment with Low Levels of Mixed Chimerism Induced by Nonmyeloablative Regimen Using Cyclophosphamide in Mice Cancer Res., November 1, 2005; 65(21): 10032 - 10040. [Abstract] [Full Text] [PDF] S.-A. Xue, L. Gao, D. Hart, R. Gillmore, W. Qasim, A. Thrasher, J. Apperley, B. Engels, W. Uckert, E. Morris, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells Blood, November 1, 2005; 106(9): 3062 - 3067. [Abstract] [Full Text] [PDF] C. Lotze, F. Schuler, W. H. Kruger, C. Hirt, M. Kirsch, S. Vogelgesang, C. A. Schmidt, and G. Dolken Combined immunoradiotherapy induces long-term remission of CNS relapse of peripheral, diffuse, large-cell lymphoma after allogeneic stem cell transplantation: Case study Neuro-oncol, October 1, 2005; 7(4): 508 - 510. [Abstract] [PDF] J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia Blood, August 1, 2005; 106(3): 938 - 945. [Abstract] [Full Text] [PDF] C. J. Wu, M. Biernacki, J. L. Kutok, S. Rogers, L. Chen, X.-F. Yang, R. J. Soiffer, and J. Ritz Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells Clin. Cancer Res., June 15, 2005; 11(12): 4504 - 4511. [Abstract] [Full Text] [PDF] M. W. N. Deininger Adoptive immunotherapy of murine CML: navigating between Scylla and Charybdis Blood, December 15, 2004; 104(13): 3843 - 3843. [Full Text] [PDF] D. S. Krause and R. A. Van Etten Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model Blood, December 15, 2004; 104(13): 4236 - 4244. [Abstract] [Full Text] [PDF] Y. Takahashi and R. W. Childs Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S. [Abstract] [Full Text] [PDF] D. J. DeAngelo, E. P. Hochberg, E. P. Alyea, J. Longtine, S. Lee, I. Galinsky, B. Parekkedon, J. Ritz, J. H. Antin, R. M. Stone, et al. Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft-versus-Host Disease Clin. Cancer Res., August 1, 2004; 10(15): 5065 - 5071. [Abstract] [Full Text] [PDF] P. Bader, H. Kreyenberg, W. Hoelle, G. Dueckers, R. Handgretinger, P. Lang, B. Kremens, D. Dilloo, K.-W. Sykora, M. Schrappe, et al. Increasing Mixed Chimerism Is an Important Prognostic Factor for Unfavorable Outcome in Children With Acute Lymphoblastic Leukemia After Allogeneic Stem-Cell Transplantation: Possible Role For Pre-Emptive Immunotherapy? J. Clin. Oncol., May 1, 2004; 22(9): 1696 - 1705. [Abstract] [Full Text] [PDF] M. H.M. Heemskerk, M. Hoogeboom, R. Hagedoorn, M. G.D. Kester, R. Willemze, and J.H. F. Falkenburg Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer J. Exp. Med., April 5, 2004; 199(7): 885 - 894. [Abstract] [Full Text] [PDF] R. W. Childs Evolving trends in hematopoietic cell transplantation for solid tumors: tempering enthusiasm with clinical reality Ann. Onc., April 1, 2004; 15(4): 543 - 544. [Full Text] [PDF] M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF] K. S. Peggs, K. Thomson, D. P. Hart, J. Geary, E. C. Morris, K. Yong, A. H. Goldstone, D. C. Linch, and S. Mackinnon Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses Blood, February 15, 2004; 103(4): 1548 - 1556. [Abstract] [Full Text] [PDF] H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF] W. A. Bethge, U. Hegenbart, M. J. Stuart, B. E. Storer, M. B. Maris, M. E. D. Flowers, D. G. Maloney, T. Chauncey, B. Bruno, E. Agura, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Blood, February 1, 2004; 103(3): 790 - 795. [Abstract] [Full Text] [PDF] T. Tamura, H. J. Kong, C. Tunyaplin, H. Tsujimura, K. Calame, and K. Ozato ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells Blood, December 15, 2003; 102(13): 4547 - 4554. [Abstract] [Full Text] [PDF] M. H. M. Heemskerk, M. Hoogeboom, R. A. de Paus, M. G. D. Kester, M. A. W. G. van der Hoorn, E. Goulmy, R. Willemze, and J. H. F. Falkenburg Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region Blood, November 15, 2003; 102(10): 3530 - 3540. [Abstract] [Full Text] [PDF] N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood, November 15, 2003; 102(10): 3829 - 3836. [Abstract] [Full Text] [PDF] J. H. Antin A 41-Year-Old Woman With Chronic Myelogenous Leukemia JAMA, August 27, 2003; 290(8): 1083 - 1090. [Full Text] [PDF] M. Renga, P. Pedrazzoli, and S. Siena Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors Ann. Onc., August 1, 2003; 14(8): 1177 - 1184. [Abstract] [Full Text] [PDF] A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions Blood, July 15, 2003; 102(2): 740 - 748. [Abstract] [Full Text] [PDF] M. Weber, C. Lange, W. Gunther, M. Franz, E. Kremmer, and H.-J. Kolb Minor Histocompatibility Antigens on Canine Hemopoietic Progenitor Cells J. Immunol., June 15, 2003; 170(12): 5861 - 5868. [Abstract] [Full Text] [PDF] W. A. E. Marijt, M. H. M. Heemskerk, F. M. Kloosterboer, E. Goulmy, M. G. D. Kester, M. A. W. G. van der Hoorn, S. A. P. van Luxemburg-Heys, M. Hoogeboom, T. Mutis, J. W. Drijfhout, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia PNAS, March 4, 2003; 100(5): 2742 - 2747. [Abstract] [Full Text] [PDF] A. Worth, K. Rao, D. Webb, J. Chessells, J. Passmore, and P. Veys Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion Blood, March 1, 2003; 101(5): 1713 - 1714. [Abstract] [Full Text] [PDF] A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al. Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission J. Clin. Oncol., February 15, 2003; 21(4): 615 - 623. [Abstract] [Full Text] [PDF] R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood, January 15, 2003; 101(2): 441 - 445. [Abstract] [Full Text] [PDF] M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Blood, January 15, 2003; 101(2): 640 - 648. [Abstract] [Full Text] [PDF] J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF] R. F. Storb, G. Lucarelli, P. A. McSweeney, and R. W. Childs Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors Hematology, January 1, 2003; 2003(1): 372 - 397. [Abstract] [Full Text] [PDF] X.-F. Yang, C. J. Wu, L. Chen, E. P. Alyea, C. Canning, P. Kantoff, R. J. Soiffer, G. Dranoff, and J. Ritz CML28 Is a Broadly Immunogenic Antigen, Which Is Overexpressed in Tumor Cells Cancer Res., October 1, 2002; 62(19): 5517 - 5522. [Abstract] [Full Text] [PDF] E. Litvinova, S. Maury, O. Boyer, S. Bruel, L. Benard, G. Boisserie, D. Klatzmann, and J. L. Cohen Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease Blood, August 28, 2002; 100(6): 2020 - 2025. [Abstract] [Full Text] [PDF] A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants Blood, August 13, 2002; 100(5): 1894 - 1902. [Abstract] [Full Text] [PDF] M. Y. Mapara, Y.-M. Kim, S.-P. Wang, R. Bronson, D. H. Sachs, and M. Sykes Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells Blood, August 13, 2002; 100(5): 1903 - 1909. [Abstract] [Full Text] [PDF] C. Guglielmi, W. Arcese, F. Dazzi, R. Brand, D. Bunjes, L. F. Verdonck, A. Schattenberg, H.-J. Kolb, P. Ljungman, A. Devergie, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose Blood, June 28, 2002; 100(2): 397 - 405. [Abstract] [Full Text] [PDF] M. Alizadeh, M. Bernard, B. Danic, C. Dauriac, B. Birebent, C. Lapart, T. Lamy, P.-Y. Le Prise, A. Beauplet, D. Bories, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction Blood, May 29, 2002; 99(12): 4618 - 4625. [Abstract] [Full Text] [PDF] M. Bregni, A. Dodero, J. Peccatori, A. Pescarollo, M. Bernardi, I. Sassi, C. Voena, A. Zaniboni, C. Bordignon, and P. Corradini Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood, May 13, 2002; 99(11): 4234 - 4236. [Abstract] [Full Text] [PDF] D. J. Weisdorf, C. Anasetti, J. H. Antin, N. A. Kernan, C. Kollman, D. Snyder, E. Petersdorf, G. Nelson, and P. McGlave Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation Blood, March 15, 2002; 99(6): 1971 - 1977. [Abstract] [Full Text] [PDF] T. Teshima, C. Liu, K. P. Lowler, G. Dranoff, and J. L. M. Ferrara Donor Leukocyte Infusion from Immunized Donors Increases Tumor Vaccine Efficacy after Allogeneic Bone Marrow Transplantation Cancer Res., February 1, 2002; 62(3): 796 - 800. [Abstract] [Full Text] [PDF] R. Chakraverty, K. Peggs, R. Chopra, D. W. Milligan, P. D. Kottaridis, S. Verfuerth, J. Geary, D. Thuraisundaram, K. Branson, S. Chakrabarti, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood, February 1, 2002; 99(3): 1071 - 1078. [Abstract] [Full Text] [PDF] E. M. Kang, M. de Witte, H. Malech, R. A. Morgan, S. Phang, C. Carter, S. F. Leitman, R. Childs, A. J. Barrett, R. Little, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome Blood, January 15, 2002; 99(2): 698 - 701. [Abstract] [Full Text] [PDF] P. Corradini, C. Tarella, A. Olivieri, A. M. Gianni, C. Voena, F. Zallio, M. Ladetto, M. Falda, M. Lucesole, A. Dodero, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies Blood, January 1, 2002; 99(1): 75 - 82. [Abstract] [Full Text] [PDF] J. P. Radich, T. Gooley, E. Bryant, T. Chauncey, R. Clift, L. Beppu, S. Edmands, M. E. D. Flowers, K. Kerkof, R. Nelson, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation Blood, September 15, 2001; 98(6): 1701 - 1707. [Abstract] [Full Text] [PDF] M. Uzunel, J. Mattsson, M. Jaksch, M. Remberger, and O. Ringden The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia Blood, September 15, 2001; 98(6): 1982 - 1985. [Abstract] [Full Text] [PDF] U. M. Saarinen-Pihkala, G. Gustafsson, O. Ringden, C. Heilmann, A. Glomstein, G. Lonnerholm, J. Abrahamsson, A. N. Bekassy, H. Schroeder, and L. Mellander No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission J. Clin. Oncol., July 15, 2001; 19(14): 3406 - 3414. [Abstract] [Full Text] [PDF] P. A. McSweeney, D. Niederwieser, J. A. Shizuru, B. M. Sandmaier, A. J. Molina, D. G. Maloney, T. R. Chauncey, T. A. Gooley, U. Hegenbart, R. A. Nash, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood, June 1, 2001; 97(11): 3390 - 3400. [Abstract] [Full Text] [PDF] B. J. Druker, C. L. Sawyers, R. Capdeville, J. M. Ford, M. Baccarani, and J. M. Goldman Chronic Myelogenous Leukemia Hematology, January 1, 2001; 2001(1): 87 - 112. [Abstract] [Full Text] [PDF] R. F. Storb, R. Champlin, S. R. Riddell, M. Murata, S. Bryant, and E. H. Warren Non-Myeloablative Transplants for Malignant Disease Hematology, January 1, 2001; 2001(1): 375 - 391. [Abstract] [Full Text] [PDF] F. Dazzi, R. M. Szydlo, N. C. P. Cross, C. Craddock, J. Kaeda, E. Kanfer, K. Cwynarski, E. Olavarria, A. Yong, J. F. Apperley, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia Blood, October 15, 2000; 96(8): 2712 - 2716. [Abstract] [Full Text] [PDF] L. D. Anderson Jr., S. Mori, S. Mann, C. A. Savary, and C. A. Mullen Pretransplant Tumor Antigen-specific Immunization of Allogeneic Bone Marrow Transplant Donors Enhances Graft-versus-Tumor Activity without Exacerbation of Graft-versus-Host Disease Cancer Res., October 1, 2000; 60(20): 5797 - 5802. [Abstract] [Full Text] P. D. Kottaridis, D. W. Milligan, R. Chopra, R. K. Chakraverty, S. Chakrabarti, S. Robinson, K. Peggs, S. Verfuerth, R. Pettengell, J. C. W. Marsh, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood, October 1, 2000; 96(7): 2419 - 2425. [Abstract] [Full Text] [PDF] R. Childs, A. Chernoff, N. Contentin, E. Bahceci, D. Schrump, S. Leitman, E. J. Read, J. Tisdale, C. Dunbar, W. M. Linehan, et al. Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation N. Engl. J. Med., September 14, 2000; 343(11): 750 - 758. [Abstract] [Full Text] [PDF] C. L. Rossetto and J. E. McMahon Current and Future Trends in Transfusion Therapy Journal of Pediatric Oncology Nursing, July 1, 2000; 17(3): 160 - 173. [Abstract] [PDF] C. Craddock, R. M. Szydlo, J. P. Klein, F. Dazzi, E. Olavarria, F. van Rhee, C. Pocock, K. Cwynarski, J. F. Apperley, and J. M. Goldman Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission Blood, July 1, 2000; 96(1): 86 - 90. [Abstract] [Full Text] [PDF] S. Verfuerth, K. Peggs, P. Vyas, L. Barnett, R. J. O'Reilly, and S. Mackinnon Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire Blood, June 15, 2000; 95(12): 3990 - 3995. [Abstract] [Full Text] [PDF] M. R. Bishop, S. R. Tarantolo, Z. S. Pavletic, J. C. Lynch, M. E. Morris, D. Zacharias, J. O. Armitage, and A. Kessinger Filgrastim as an Alternative to Donor Leukocyte Infusion for Relapse After Allogeneic Stem-Cell Transplantation J. Clin. Oncol., June 11, 2000; 18(11): 2269 - 2272. [Abstract] [Full Text] [PDF] C. Guglielmi, W. Arcese, J. Hermans, A. Bacigalupo, G. Bandini, D. Bunjes, E. Carreras, A. Devergie, F. Frassoni, J. Goldman, et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis Blood, June 1, 2000; 95(11): 3328 - 3334. [Abstract] [Full Text] [PDF] C.-M. Seong, S. Giralt, H. Kantarjian, J. Xu, J. Swantkowski, K. Hayes, A. B. Glassman, I. Khouri, M. Korbling, P. Thall, et al. Early Detection of Relapse by Hypermetaphase Fluorescence In Situ Hybridization After Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia J. Clin. Oncol., May 9, 2000; 18(9): 1831 - 1836. [Abstract] [Full Text] [PDF] L. Gao, I. Bellantuono, A. Elsasser, S. B. Marley, M. Y. Gordon, J. M. Goldman, and H. J. Stauss Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1 Blood, April 1, 2000; 95(7): 2198 - 2203. [Abstract] [Full Text] [PDF] J. Pinilla-Ibarz, K. Cathcart, T. Korontsvit, S. Soignet, M. Bocchia, J. Caggiano, L. Lai, J. Jimenez, J. Kolitz, and D. A. Scheinberg Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses Blood, March 1, 2000; 95(5): 1781 - 1787. [Abstract] [Full Text] [PDF] D. L. Porter, R. H. Collins Jr, C. Hardy, N. A. Kernan, W. R. Drobyski, S. Giralt, M. E.D. Flowers, J. Casper, A. Leahey, P. Parker, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions Blood, February 15, 2000; 95(4): 1214 - 1221. [Abstract] [Full Text] [PDF] C. J. Link, T. Seregina, A. Traynor, and R. K. Burt Cellular Suicide Therapy of Malignant Disease Oncologist, February 1, 2000; 5(1): 68 - 74. [Abstract] [Full Text]

	Copyright © 1990 by American Society of Hematology         Online ISSN: 1528-0020